Systematic review highlights elevated Beta‐2 Microglobulin tied to poor overall survival in DLBCL patients, suggesting it as a key prognostic marker.
Background Evidence indicates that beta‐2 microglobulin (β2M) plays a prognostic role in patients with diffuse large B‐cell lymphoma (DLBCL). Aim However, due to controversies among previous studies, this meta‐analysis was conducted to evaluate the prognostic role of β2M in DLBCL patients. Methods and Results Relevant studies were identified through a systematic search using specific keywords in PubMed/Medline, Scopus, and Web of Science databases. Studies that provided complete information on the hazard ratio with a 95% confidence interval for β2M with respect to overall survival (OS) and progression‐free survival (PFS) in multivariate models were included in the meta‐analysis. A total of 30 studies, encompassing 25 128 patients, were included in this meta‐analysis. The pooled analysis demonstrated a significant association between elevated β2M levels and poor OS in DLBCL patients (HR Pooled : 1.65, 95% CI: 1.45–1.88, p ‐value < 0.01). Similarly, increased β2M levels were significantly associated with lower PFS in DLBCL patients (HR Pooled : 1.54, 95% CI: 1.39–1.70, p ‐value < 0.01). Conclusion The available evidence suggests that β2M serves as an independent prognostic marker with significant effects on OS and PFS in DLBCL patients. Elevated serum β2M levels are associated with poor prognosis and worse OS and PFS outcomes in DLBCL patients.
No takes yet. Share an insight, caveat, or question.
Disfani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: